Taiho Pharmaceutical Co Ltd - Company Profile
Powered by 
All the sales intelligence you need on Taiho Pharmaceutical Co Ltd in one solution.
- Save hours of research time with a comprehensive
Sales Intelligence Solution.
- Understand how Taiho Pharmaceutical Co Ltd fits into your total
addressable market and Ideal Customer Profile.
- Gain competitive edge with triggers that tell you
when and how to engage with Taiho Pharmaceutical Co Ltd.
Get in touch about GlobalData Company reports
Contact the team or request a demo to find out how our data can drive your business forward
Taiho Pharmaceutical Co Ltd (Taiho), a subsidiary of Otsuka Group, is a global pharmaceutical company primarily engaged in the research, development, and supply of pharmaceutical products. The company's major activities include the development of innovative drugs, particularly in the areas of oncology and immune-related diseases. Taiho's major products include a range of prescription drugs, such as Lonsurf and other consumer healthcare products. The company serves a broad customer base, including patients, healthcare professionals, and medical staff, providing solutions for various health conditions and diseases. The company's products are available worldwide. The company operates globally, with business locations in the US, Europe, Asia, and Oceania. Taiho is headquartered in Tokyo, Japan
Headquarters
Japan
Address
1-27 Kandanishiki-Cho, Chiyoda, Tokyo, 101-8444
Website
www.taiho.co.jp
Telephone
81 3 32944527
No of Employees
2,149
Industry
Pharmaceuticals and Healthcare
Revenue (2025)
$1.4B
Taiho Pharmaceutical Co Ltd premium industry data and analytics
Products and Services
| Products | Services | Brands |
|---|---|---|
| Anti-Allergy Drugs | Formulation Development | Lytgobi |
| Liver Disease Drugs | Chemistry, Manufacturing and Control | ZOSYN |
| Antipyretic and Analgesic Drugs | Lonsurf | |
| XYZ | XYZ | |
| XYZ | XYZ | |
| XYZ | XYZ |
History
History section provides information on new products, mergers, acquisitions, expansions, approvals, and many more key events.
| Year | Event | Description |
|---|---|---|
| 2026 | Contracts/Agreements | In August, the company entered into an agreement with FUJIFILM Corporation for the development of manufacturing technologies for next-generation antibody-drug conjugates (ADCs). |
| 2026 | New Products/Services | In July, the company launched PI3Kα inhibitor, HAIZEXIN tablets 10mg. |
| 2026 | Regulatory Approval | In May, the company received U.S. Food and Drug Administration (FDA) approval for INQOVI (decitabine and cedazuridine) plus venetoclax as a treatment for adults with newly diagnosed acute myeloid leukemia (AML) who are 75 years or older. |
Competitor Comparison
| Key Parameters | Taiho Pharmaceutical Co Ltd | Chugai Pharmaceutical Co Ltd | Nippon Shinyaku Co Ltd | Kissei Pharmaceutical Co Ltd | Senju Pharmaceutical Co Ltd |
|---|---|---|---|---|---|
| Headquarters | Japan | Japan | Japan | Japan | Japan |
| City | Chiyoda | Chuo-Ku | Kyoto | Matsumoto | Chuo-Ku |
| State/Province | Tokyo | Tokyo | Kyoto | Nagano | Osaka |
| No. of Employees | 2,149 | 7,872 | 2,309 | 1,786 | 1,018 |
| Entity Type | Private | Public | Public | Public | Private |
Executives
| Name | Position | Board | Since | Age |
|---|---|---|---|---|
| Masayuki Kobayashi | President; Director | Executive Board | - | - |
| Atsushi Azuma | Managing Director | Executive Board | - | - |
| Tatsuya Niki | Managing Director | Executive Board | - | - |
| Takeshi Sagara | Director | Non Executive Board | - | - |
| Noriyuki Takahashi | Director | Non Executive Board | - | - |
| Non Dignissim Eros | Proin vel | Convallis | 2026 | XY |
| Non Dignissim Eros | Proin vel | Convallis | 2026 | XY |
| Non Dignissim Eros | Proin vel | Convallis | 2026 | XY |
Still looking?
Have you found what you were looking for? From start-ups to market leaders, uncover what they do and how they do it.
Explorer
Access more premium companies when you subscribe to Explorer